Telix Pharmaceuticals Statistics

Total Valuation

Telix Pharmaceuticals has a market cap or net worth of 5.18 billion. The enterprise value is 5.12 billion.

Market Cap	5.18B
Enterprise Value	5.12B

Important Dates

The next estimated earnings date is Thursday, February 20, 2025.

Earnings Date	Feb 20, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+5.90%
Shares Change (QoQ)	+4.39%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	282.73M

Valuation Ratios

The trailing PE ratio is 157.79.

PE Ratio	157.79
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	1,728.06
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 109.70, with an EV/FCF ratio of 200.02.

EV / Earnings	155.94
EV / Sales	12.67
EV / EBITDA	109.70
EV / EBIT	121.50
EV / FCF	200.02

Financial Position

The company has a current ratio of 0.99, with a Debt / Equity ratio of 0.05.

Current Ratio	0.99
Quick Ratio	0.81
Debt / Equity	0.05
Debt / EBITDA	0.30
Debt / FCF	0.58
Interest Coverage	75.00

Financial Efficiency

Return on equity (ROE) is 20.49% and return on invested capital (ROIC) is 16.34%.

Return on Equity (ROE)	20.49%
Return on Assets (ROA)	7.97%
Return on Capital (ROIC)	16.34%
Revenue Per Employee	1.02M
Profits Per Employee	77,580
Employee Count	234
Asset Turnover	1.22
Inventory Turnover	11.07

Taxes

In the past 12 months, Telix Pharmaceuticals has paid 5.08 million in taxes.

Income Tax	5.08M
Effective Tax Rate	18.57%

Stock Price Statistics

The stock price has increased by +142.42% in the last 52 weeks. The beta is 2.40, so Telix Pharmaceuticals's price volatility has been higher than the market average.

Beta (5Y)	2.40
52-Week Price Change	+142.42%
50-Day Moving Average	14.97
200-Day Moving Average	12.26
Relative Strength Index (RSI)	54.43
Average Volume (20 Days)	4,381

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Telix Pharmaceuticals had revenue of 430.80 million and earned 32.82 million in profits. Earnings per share was 0.10.

Revenue	430.80M
Gross Profit	270.45M
Operating Income	44.94M
Pretax Income	33.41M
Net Income	32.82M
EBITDA	48.80M
EBIT	44.94M
Earnings Per Share (EPS)	0.10

Full Income Statement

Balance Sheet

The company has 79.29 million in cash and 14.77 million in debt, giving a net cash position of 64.51 million.

Cash & Cash Equivalents	79.29M
Total Debt	14.77M
Net Cash	64.51M
Net Cash Per Share	n/a
Equity (Book Value)	269.53M
Book Value Per Share	0.81
Working Capital	-2.08M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 33.16 million and capital expenditures -7.58 million, giving a free cash flow of 25.59 million.

Operating Cash Flow	33.16M
Capital Expenditures	-7.58M
Free Cash Flow	25.59M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 62.78%, with operating and profit margins of 10.43% and 7.62%.

Gross Margin	62.78%
Operating Margin	10.43%
Pretax Margin	7.75%
Profit Margin	7.62%
EBITDA Margin	11.33%
EBIT Margin	10.43%
FCF Margin	5.94%

Dividends & Yields

Telix Pharmaceuticals does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-5.90%
Shareholder Yield	-5.90%
Earnings Yield	n/a
FCF Yield	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Telix Pharmaceuticals has an Altman Z-Score of 7.5 and a Piotroski F-Score of 8.

Altman Z-Score	7.5
Piotroski F-Score	8